Influenza Vaccine Market Share, Size, Trends, Analysis, Key Players, Latest Insights, Opportunity and Forecast to 2027

Comments · 60 Views

The Influenza Vaccine Market is expected to reach US$ 9.1 Billion by 2027, exhibiting a CAGR of 7.9% during 2022-2027.

According to IMARC Group’s latest report, titled “Influenza Vaccine Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2022-2027”, offers a comprehensive analysis of the industry, which comprises insights on the influenza vaccine market share.

The global influenza vaccine market size reached US$ 5.9 Billion in 2021. Looking forward, IMARC Group expects the market to reach US$ 9.1 Billion by 2027, exhibiting a CAGR of 7.9% during 2022-2027. Influenza is an infection of the throat, lungs, and nose. Common symptoms include head and body aches, cough, fever, and a stuffy or runny nose. Influenza vaccines or flu shots are biological preparations that protect against and prevent severe infections caused by the influenza virus. The vaccines used for influenza are formulated using three different influenza viruses, including influenza type A and B with H3N2 and H1N1 virus strains. These therapeutics are mainly available in inactivated, adjuvant, live attenuated, and recombinant influenza vaccines. Currently, governments of various nations have mandated immunization against influenza among children aged six months to five. 

Get a Free Sample Copy of this Report:

Influenza Vaccine Market Trends:

The rising prevalence of influenza and the fueling awareness regarding influenza vaccines are some of the factors primarily driving the market growth. This is further supported by the steadily increasing geriatric population and surging research and development (RD) activities across the globe. In addition to this, governments of various countries are introducing free seasonal influenza vaccination programs for all age groups, which, in turn, is providing a boost to the market growth. In line with this, key market players are actively working to develop new vaccines with better efficacy, which is accelerating the market growth. Other factors, such as growing healthcare expenditure and rising clinical trials, are creating a positive outlook for the market.

Influenza Vaccine Market 2022-2027 Competitive Analysis and Segmentation:

Competitive Landscape With Key Players:

The competitive landscape of the influenza vaccine market has been studied in the report with the detailed profiles of the key players operating in the market.

Some of these key players include:

  • Abbott Laboratories
  • AstraZeneca plc
  • CSL Limited
  • Daiichi Sankyo Company Limited
  • Emergent BioSolutions Inc.
  • F. Hoffmann-La Roche AG
  • Gamma Vaccines Pty Ltd
  • GlaxoSmithKline plc
  • Merck Co. Inc.
  • Novartis AG
  • Pfizer Inc.
  • Sanofi

Key Market Segmentation:

The report has segmented the influenza vaccine market on the basis of breakup by vaccine type, technology, age group, route of administration and region.

Breakup by Vaccine Type:

  • Quadrivalent
  • Trivalent

Breakup by Technology:

  • Egg-based
  • Cell-based

Breakup by Age Group:

  • Pediatric
  • Adult

Breakup by Route of Administration:

  • Injection
  • Nasal Spray

Breakup by Region:

  • North America (United States, Canada)
  • Europe (Germany, France, United Kingdom, Italy, Spain, Russia, Others)
  • Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, Others)
  • Latin America (Brazil, Mexico, Others)
  • Middle East and Africa (United Arab Emirates, Saudi Arabia, Turkey, South Africa, Others)

Ask Analyst for Customization and Explore Full Report With TOC List of Figures:

Key Highlights of the Report:

  • Market Performance (2016-2021)
  • Market Outlook (2022-2027)
  • Market Trends
  • Market Drivers and Success Factors
  • Impact of COVID-19
  • Value Chain Analysis
  • Comprehensive mapping of the competitive landscape

If you need specific information that is not currently within the scope of the report, we will provide it to you as a part of the customization.

About Us

IMARC Group is a leading market research company that offers management strategy and market research worldwide. We partner with clients in all sectors and regions to identify their highest-value opportunities, address their most critical challenges, and transform their businesses.

IMARC’s information products include major market, scientific, economic and technological developments for business leaders in pharmaceutical, industrial, and high technology organizations. Market forecasts and industry analysis for biotechnology, advanced materials, pharmaceuticals, food and beverage, travel and tourism, nanotechnology and novel processing methods are at the top of the company’s expertise.

Our offerings include comprehensive market intelligence in the form of research reports, production cost reports, feasibility studies, and consulting services. Our team, which includes experienced researchers and analysts from various industries, is dedicated to providing high-quality data and insights to our clientele, ranging from small and medium businesses to Fortune 1000 corporations.

Contact US:
30 N Gould St, Ste R
Sheridan, WY 82801, USA
Americas: +1-631-791-1145 | Europe Africa: +44-753-713-2163 | Asia: +91-120-433-0800